Puma Biotechnology reports developments for a biopharmaceutical company built around oncology drug commercialization and development. Company news commonly centers on NERLYNX®, its oral neratinib product for HER2-positive breast cancer, including net product revenue, cost of sales, royalty revenue and financial outlook tied to demand for the therapy.
Updates also cover alisertib, a selective, orally administered aurora kinase A inhibitor licensed for development and commercialization. Puma describes the ALISCA™-Lung1 Phase II trial in extensive-stage small cell lung cancer and the ALISCA™-Breast1 Phase II trial in HER2-negative, HR-positive metastatic breast cancer, along with employee inducement equity awards under Nasdaq Listing Rule 5635(c)(4) and investor conference activity.
Puma Biotechnology (NASDAQ: PBYI) announced the publication of Phase II results for alisertib in treating endocrine-resistant advanced breast cancer in JAMA Oncology. The trial involved 91 postmenopausal women, assessing alisertib alone and in combination with fulvestrant. Key findings include a 19.6% overall response rate for alisertib alone, with a median duration of response of 15.1 months. In the combination arm, a 20.0% response rate was noted with a median duration of 8.5 months. The trial indicated a tolerable safety profile, although adverse events such as neutropenia and anemia were reported. Positive results support further development of alisertib.
Summit Therapeutics (SMMT) reported its financial results for the fourth quarter and year ending December 31, 2022. The company is progressing with its Collaboration and License Agreement with Akeso, acquiring rights to ivonescimab, a bispecific antibody for cancer treatment, for an upfront payment of $500 million. Key financials include a net loss of $78.8 million for the year, a significant decrease from $88.6 million in 2021. Summit raised $500 million in a Rights Offering to fund ongoing operations, with sufficient capital expected to cover expenses into late 2024. An earnings call is scheduled for March 9, 2023.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on March 1, 2023, that its Compensation Committee approved an inducement restricted stock unit award of 9,375 shares to a new non-executive employee. This award, granted under the 2017 Employment Inducement Incentive Award Plan, vests over three years with specific milestones tied to the employee's service. Puma focuses on developing innovative cancer care products, including NERLYNX® for HER2-positive breast cancer. The company also has an exclusive license for alisertib, aimed at treating small cell lung cancer and breast cancer.
Puma Biotechnology reported its financial results for the fourth quarter and full year 2022. For Q4 2022, product revenue, net from NERLYNX sales, reached $53.7 million, up from $51.0 million in Q4 2021. For the full year, product revenue totaled $200.0 million, a rise from $189.1 million in 2021. The company experienced a net loss of $5.6 million in Q4 2022 versus a net income of $4.2 million in the same period last year. Adjusted net loss stood at $3.0 million in Q4 2022, while total revenue for the year was $228.0 million. The company holds $81.1 million in cash at year-end.
Puma Biotechnology (NASDAQ: PBYI) announced its participation in Cowen's 43rd Annual Health Care Conference from March 6-8, 2023, at the Boston Marriott Copley Place. Alan H. Auerbach, the company’s Chairman and CEO, will join a Breast and Lung Cancer Panel Discussion on March 7 at 10:30 a.m. ET. A live webcast will be available at this link, with a replay accessible for 30 days on Puma’s website. Puma is known for its innovative cancer care solutions, including NERLYNX (neratinib), which is FDA-approved for various HER2-positive breast cancer treatments.
Puma Biotechnology (NASDAQ: PBYI) will hold a conference call on March 2, 2023, at 1:30 p.m. PST to discuss its fourth quarter and full year 2022 financial results. Investors can join the call by dialing 1-877-709-8150 for domestic or 1-201-689-8354 for international access. The call will also feature a live webcast available on the company’s website, which will be archived for 90 days.
Puma, focused on innovative cancer care solutions, markets NERLYNX (neratinib), approved by the FDA in 2017. They have also licensed alisertib for small cell lung cancer and breast cancer treatment.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on February 6, 2023 that its Compensation Committee approved the grant of inducement restricted stock unit awards covering 34,163 shares to four new non-executive employees. The awards are part of Puma's 2017 Employment Inducement Incentive Award Plan and will vest over a three-year period, promoting employee retention. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent to bolster the company’s biopharmaceutical development efforts.
Puma Biotechnology (NASDAQ: PBYI) announced that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines for Breast Cancer to include neratinib (NERLYNX®) as a category 2B therapy for ER+/HER2- or ER-/HER2- metastatic breast cancer with activating HER2 mutations. This update highlights neratinib's use in combination with fulvestrant and trastuzumab. The decision is based on results from the Phase 2 SUMMIT and MutHER trials. Additionally, the NCCN has included a dose escalation schedule for neratinib for better tolerability. The update reflects growing recognition of neratinib's potential in treating advanced breast cancer.
Puma Biotechnology (NASDAQ: PBYI) will present an overview of its operations at the B. Riley Securities’ 3rd Annual Oncology Conference on January 19 at 11:00 a.m. PST. The presentation by CEO Alan H. Auerbach will be accessible via live webcast at this link.
Puma focuses on developing innovative cancer treatments, including NERLYNX® for HER2-positive breast cancer. Additionally, they are advancing alisertib for small cell lung cancer and breast cancer after securing a license in September 2022.
Puma Biotechnology, Inc. (NASDAQ: PBYI) announced on January 10, 2023, the grant of 22,250 inducement restricted stock unit awards to four new non-executive employees. These awards, approved by the Compensation Committee, will vest over three years, with the first third vesting one year after the commencement date for each employee. This initiative aims to attract talent under Puma's 2017 Employment Inducement Incentive Award Plan. Puma focuses on developing innovative cancer treatments, including NERLYNX® for breast cancer and alisertib for small cell lung cancer.